US › Healthcare

Aytu BioScience Inc (AYTU)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$2.04+1.49%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$16.1M

Revenue YoY

+6.4%

Net profit

$-15,000

EPS

$-0.05

EPS estimate

$-0.22

Net margin

-0.1%

EPS came in at -0.05 against a street estimate of -0.22 — a beat of 77.3%.

Key statistics

Market cap

$22.2M

Forward P/E

9.2

P/B

0.71

Book value

$3.29

EPS (TTM)

$-1.16

52-week high

$3.07

52-week low

$1.80

50-day MA

$2.18

200-day MA

$2.36

Beta

0.18

Analyst view

Analysts rate Aytu BioScience Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $9.67.

Shareholding

Insiders

8.16%

Institutions

35.51%

Largest institutional holders

Fund	Stake
Nantahala Capital Management, LLC	20.00%
Stonepine Capital Management Llc	8.40%
Awm Investment Company Inc	5.70%
Vanguard Capital Management, LLC	2.40%
CROWN ADVISORS MANAGEMENT, INC.	1.84%
Diadema Partners LP	1.37%
Two Sigma Investments LLC	0.97%
Renaissance Technologies Corp	0.96%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aytu BioScience Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.